Catalent Inc. [CTLT] Pres. Clinical Dev Supply Div makes an insider purchase of 2,216 shares worth 0.2 million.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Catalent Inc. shares valued at $198,531 were sold by Hopson Ricky on Aug 31. At $89.59 per share, Hopson Ricky sold 2,216 shares. The insider’s holdings dropped to 17,095 shares worth approximately $1.35 million following the completion of this transaction.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Also, Gunther Scott sold 1,639 shares, netting a total of over 170,571 in proceeds. Following the sale of shares at $104.07 each, the insider now holds 23,988 shares.

Before that, Riley Michael A. had sold 2,491 shares from its account. In a trade valued at $259,238, the Pres. Bio Product Delivery Div traded Catalent Inc. shares for $104.07 each. Upon closing the transaction, the insider’s holdings decreased to 2,491 shares, worth approximately $0.52 million.

As published in their initiating research note from Barclays on December 16, 2021, Catalent Inc. [CTLT] has been an Overweight and the price target has been revised to $160. This represents a 50.59% premium over Thursday’s closing price. Analysts at KeyBanc Capital Markets upgraded the stock from ‘”a Sector weight”‘ to ‘”an Overweight”‘ outlook in a report released in early December. As of June 25, 2020, Argus has initiated its “Buy” rating for CTLT. Earlier on April 21, 2020, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CTLT stock.

Analyzing CTLT’s Price Performance

On Thursday, Catalent Inc. [NYSE: CTLT] plunged -4.92% to $79.06. The stock’s lowest price that day was $79.04, but it reached a high of $82.73 in the same session. During the last five days, there has been a drop of approximately -11.41%. Over the course of the year, Catalent Inc. shares have dropped approximately -38.25%. Shares of the company reached a 52-week high of $128.26 on 01/03/22 and a 52-week low of $79.04 on 09/22/22. A 50-day SMA is recorded $100.91, while a 200-day SMA reached $104.75. Nevertheless, trading volume fell to 2.21 million shares from 1.47 million shares the previous day.

Support And Resistance Levels for Catalent Inc. (CTLT)

According to the 24-hour chart, there is a support level at 77.82, which, if violated, would cause prices to drop to 76.59. In the upper region, resistance lies at 81.51. The next price resistance is at 83.97. RSI (Relative Strength Index) is 23.55 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -6.54, which suggests the price will decrease in the coming days. Percent R is at 99.89%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Catalent Inc. subject to short interest?

Stocks of Catalent Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.8 million shares to 3.92 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 4.72 million shares. A decline of -20.41% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.65 of the overall float, the days-to-cover ratio (short ratio) decline to 3.65.

Which companies own the most shares of Catalent Inc. (CTLT)?

According to T. Rowe Price Associates, Inc. filings, the company currently owns 22,303,561 shares, which is about 12.45% of the total CTLT shares outstanding. The investor’s shares have appreciated by 2,011,520 from its previous 13-F filing of 20292041.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $1,613,156,600. Capital Research & Management Co acquire a 17.92% interest valued at $906.39 million while BlackRock Fund Advisors sold a -421,609 stake. A total of -66,683 shares of Catalent Inc. were sold by SSgA Funds Management, Inc. during the quarter, and -497,854 were sold by Janus Henderson Investors US LLC. In its current portfolio, Veritas Asset Management LLP holds 6,892,041 shares valued at $606.5 million.

In terms of Catalent Inc. share price expectations, FactSet research, analysts set an average price target of $123.75 in the next 12 months, up nearly 50.33% from the previous closing price of $83.15. Analysts anticipate Catalent Inc. stock to reach $145.00 by 2022, with the lowest price target being $105.00. In spite of this, 15 analysts ranked Catalent Inc. stock as a Buy at the end of 2022.


Please enter your comment!
Please enter your name here